Interim report for the nine months ended September 30,

Summary: For the first nine months of 2007 the Pharmexa Group generated
revenues and other operating income of DKK 15,495 thousand and a net loss of
DKK 130,972 thousand. Research and development costs totalled DKK 129,572
thousand. The Pharmexa Group retains its forecast for the full year. 


Additional information: Jakob Schmidt, Chief Executive Officer, telephone +45
4516 2525 
Claude Mikkelsen, Vice President, Corporate Affairs and Communication,
telephone +45 4516 2525 or +45 4060 2558

Interim report for the nine months ended September 30, 2007

Attachments